Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Organon & Co OGN

Healthcare Biotechnology
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSE:OGN)

New Analysis of Organon's VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

Business Wire March 8, 2025

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024

Business Wire February 13, 2025

Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025

Business Wire January 23, 2025

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire December 19, 2024

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Business Wire December 16, 2024

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Business Wire November 5, 2024

Organon Reports Results for the Third Quarter Ended September 30, 2024

Business Wire October 31, 2024

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Business Wire October 30, 2024

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

GlobeNewswire October 28, 2024
View More News ››

Opinion & Analysis (NYSE:OGN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSE:OGN)

Organon To Report Fourth Quarter and Full Year 2024 Results

BREAKING NEWS: $OGN Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025Organon...
whytestocks - January 23, 2025

Orogen Royalties Announces Another Strong Quarter in Royalty

News; $OGNRF Orogen Royalties Announces Another Strong Quarter in Royalty RevenueVANCOUVER, BC / ACCESSWIRE / November 26, 2024 / (TSXV...
whytestocks - November 26, 2024

Gold Miners are on the Brink of Exciting Returns

4,687 Views Aug 28, 2024 Tom welcomes Garrett Goggin, a seasoned financial analyst with expertise in trading and a strong emphasis on...
Betteryear2 - September 1, 2024

Orogen Royalties rakes in more cash in Q2 2024

Profitability translating into shareholder value: https://stockhouse.com/news/the-market-online-news/2024/08/26/orogen-royalties-rakes...
TrevorAbes - August 26, 2024

Organon Reports Results for the Second Quarter Ended June 30

NEWS: $OGN Organon Reports Results for the Second Quarter Ended June 30, 2024Second quarter 2024 revenue of $1.607 billion, flat year...
whytestocks - August 6, 2024

Analyst Recommendation

Last stock in the clip. Interesting that it's the only one of this top and past picks that both he and his family own personally...
retiredcf - July 20, 2024
View more Bullboard ››

Nanalysis Scientific Corp.

Nanalysis Scientific Corp.

Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for ...
View More »